Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05630989 · ClinicalTrials.gov registry record
A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy
A clinical trial of Pancreatic Ductal Adenocarcinoma, sponsored by Mandana Kamgar, MD.
- Recruiting
- Registry status
- 80
- Enrollment target
- 1
- Study location
NCT05630989 is a study of Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by Mandana Kamgar, MD. The registered enrollment target is 80 participants, below the 600-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05630989, a study of Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by Mandana Kamgar, MD.
- RECRUITING
- Registry status
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an observational precision oncology study designed to collect and analyze data that allows us to characterize the safety and efficacy of several different mitogen-activated protein kinase kinase inhibitor (MEKi) -based treatment strategies and the feasibility of administering MEKi combination therapies to patients with KRAS G12R mutated advanced pancreatic ductal adenocarcinoma (PDAC).
Conditions Studied
Interventions
- OTHER combination therapy with no MEKi
- DRUG combination therapy with MEKi-HCQ
- DRUG combination therapy with MEKi-EGFRi
- DRUG combination therapy with MEKi.
Study Locations (1)
Wisconsin
- Froedtert Hospital and the Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2023-02-07 |
| Est. Completion | 2027-08-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05630989
The ClinicalTrials.gov registry entry for NCT05630989 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 600-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (87% lower). The listed sponsor is Mandana Kamgar, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 4 interventions - of which combination therapy with no MEKi is the first listed.
NCT05630989 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05630989 about?
NCT05630989 is a clinical study titled "A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy". This is an observational precision oncology study designed to collect and analyze data that allows us to characterize the safety and efficacy of several different mitogen-activated protein kinase kinase inhibitor (MEKi) -based treatment strategies and the feasibility of administering MEKi combinatio...
What is the current status of trial NCT05630989?
This trial is currently recruiting. The enrollment target is 80 participants. The study started on 2023-02-07. Estimated completion is 2027-08-01.
What conditions does trial NCT05630989 study?
This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma.
What interventions are being tested in trial NCT05630989?
The interventions under investigation include: combination therapy with no MEKi (OTHER), combination therapy with MEKi-HCQ (DRUG), combination therapy with MEKi-EGFRi (DRUG), combination therapy with MEKi. (DRUG).
Who is sponsoring clinical trial NCT05630989?
This trial is sponsored by Mandana Kamgar, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05630989 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
RECRUITING · Phase 2
-
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
-
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.